Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Clinical trial NCT04524611 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04524611
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-30
- Primary completion
- 2028-02-01
- Enrollment
- 527
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.